










































Nuclear export and retention signals in the RS domain of SR
proteins
Citation for published version:
Cazalla, D, Zhu, J, Manche, L, Huber, E, Krainer, AR & Cáceres, JF 2002, 'Nuclear export and retention
signals in the RS domain of SR proteins' Molecular and Cellular Biology, vol. 22, no. 19, pp. 6871-82. DOI:
10.1128/MCB.22.19.6871-6882.2002
Digital Object Identifier (DOI):
10.1128/MCB.22.19.6871-6882.2002
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Molecular and Cellular Biology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
MOLECULAR AND CELLULAR BIOLOGY, Oct. 2002, p. 6871–6882 Vol. 22, No. 19
0270-7306/02/$04.000 DOI: 10.1128/MCB.22.19.6871–6882.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Nuclear Export and Retention Signals in the RS Domain of
SR Proteins
Demian Cazalla,1 Jun Zhu,2 Lisa Manche,2 Elisabeth Huber,1 Adrian R. Krainer,2 and
Javier F. Ca´ceres1*
MRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland,1 and Cold
Spring Harbor Laboratory, Cold Spring Harbor, New York 11724-22082
Received 5 April 2002/Returned for modification 3 June 2002/Accepted 20 June 2002
Splicing factors of the SR protein family share a modular structure consisting of one or two RNA recognition
motifs (RRMs) and a C-terminal RS domain rich in arginine and serine residues. The RS domain, which is
extensively phosphorylated, promotes protein-protein interactions and directs subcellular localization and—in
certain situations—nucleocytoplasmic shuttling of individual SR proteins. We analyzed mutant versions of
human SF2/ASF in which the natural RS repeats were replaced by RD or RE repeats and compared the splicing
and subcellular localization properties of these proteins to those of SF2/ASF lacking the entire RS domain or
possessing a minimal RS domain consisting of 10 consecutive RS dipeptides (RS10). In vitro splicing of a
pre-mRNA that requires an RS domain could take place when the mutant RD, RE, or RS10 domain replaced
the natural domain. The RS10 version of SF2/ASF shuttled between the nucleus and the cytoplasm in the same
manner as the wild-type protein, suggesting that a tract of consecutive RS dipeptides, in conjunction with the
RRMs of SF2/ASF, is necessary and sufficient to direct nucleocytoplasmic shuttling. However, the SR protein
SC35 has two long stretches of RS repeats, yet it is not a shuttling protein. We demonstrate the presence of a
dominant nuclear retention signal in the RS domain of SC35.
Pre-mRNA splicing takes place within the spliceosome, a
macromolecular complex composed of four small nuclear ri-
bonucleoprotein particles (snRNPs) (U1, U2, U4/U6, and U5)
and approximately 50 to 100 polypeptides (32). The SR pro-
teins are an extensively characterized family of structurally and
functionally related non-snRNP splicing factors that are essen-
tial for constitutive splicing and that also influence alternative
splicing regulation in higher eukaryotes (5, 19, 58).
The SR proteins are involved in multiple steps of the con-
stitutive splicing reaction. They promote the recruitment of the
U1 snRNP to the 5 splice site (14, 26, 29) and of the U2AF
splicing factor and U2 snRNP to the branch site or 3 splice site
(57, 62) and also facilitate the recruitment of the U4/U6-U5
tri-snRNP at later stages of the splicing reaction (51). The SR
proteins also bridge pairs of 5 and 3 splice sites via RS
domain-mediated protein-protein interactions, which can oc-
cur across an exon or an intron (exon definition or intron
definition) (50, 62). The SR proteins are also important regu-
lators of alternative splicing, and their activity is subject to
antagonism by members of the hnRNP A/B family of proteins.
Increased levels of SR proteins usually promote the selection
of proximal alternative 5 splice sites both in vitro and in vivo,
whereas an excess of hnRNPs A/B proteins usually results in
the selection of distal 5 splice sites (8, 38, 63). Tissue-specific
variations in the total and relative amounts of SR proteins and
in the molar ratio of SF2/ASF to its antagonist, hnRNP A1,
support the notion that the relative levels and activities of
these two families of antagonistic factors may be crucial in
regulating the patterns of alternative splicing in a tissue-spe-
cific or developmentally regulated manner (21, 66).
A class of related RS domain-containing proteins, termed
SR protein-related polypeptides or SR-like proteins, some of
which also contain RNA recognition motifs (RRMs), are also
involved in splicing regulation (16, 19). SR family and SR-like
proteins additionally function in the recognition of exonic
splicing enhancers, leading to the activation of otherwise inef-
ficient upstream 3 splice sites (reviewed in references 3, 19,
and 22).
The SR proteins have a modular structure consisting of one
or two RRMs followed by a C-terminal domain rich in alter-
nating serine and arginine residues (the RS domain). The RS
domain consists of simple repeats of arginine and serine, oc-
casionally interrupted by other amino acids, and its length and
sequence are highly conserved for individual SR proteins in
different species (2, 65). The functional roles of the different
domains of SR proteins in constitutive and alternative splicing
have been extensively studied. RRM modules determine sub-
strate specificity, whereas RS domains are functionally inter-
changeable and do not contribute to substrate specificity (9, 41,
59). RS domains direct protein-protein interactions (62) and
can function in splicing activation even when fused to a heter-
ologous RNA-binding domain, facts which led to the proposal
that RS domains function as activators of splicing (20).
It was originally thought that both the RRMs and the RS
domain of SR proteins are essential for constitutive splicing,
whereas the RS domain is dispensable for concentration-de-
pendent alternative splice-site switching (4, 69). However,
more recent evidence has demonstrated that the RS domain of
SF2/ASF is dispensable for the splicing of some substrates,
including several constitutive and enhancer-dependent pre-
mRNAs; the requirement for this domain is substrate specific
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and is more pronounced when the 3 splice site is weak (68).
These findings suggested the existence of an RS domain-inde-
pendent function of SR proteins in constitutive and enhancer-
dependent splicing and also suggested that—at least for the RS
domain-independent substrates—the role of SR proteins in
enhancer-dependent splicing involves functions other than
U2AF recruitment.
The RS domains of two Drosophila splicing regulators,
SWAP (suppressor of white apricot) and Tra (transformer),
direct these splicing factors to the nuclear speckles (23, 36). It
was previously determined that the SR protein RS domain acts
as a nuclear localization signal (NLS) and that, in the single-
RRM-containing SRp20, the RS domain is both necessary and
sufficient as a signal for targeting to the nuclear speckles (6). It
was also shown that whereas some human SR proteins are
confined to the nucleus, three of them—SF2/ASF, SRp20, and
9G8—shuttle continuously between the nucleus and the cyto-
plasm and that this property is conferred by the RS domain
and is affected by RS domain phosphorylation (7). Thus, the
RS domain, which is extensively phosphorylated, not only pro-
motes interactions with other splicing factors but also directs
the subcellular localization and nucleocytoplasmic shuttling of
individual SR proteins (6, 62).
In this report, we analyze the activities of a series of mutant
versions of the RS domain of SF2/ASF in constitutive splicing,
subcellular localization, and nucleocytoplasmic shuttling. We
report that alternating arginine and acidic residues appear to
mimic the structural and functional properties of a phosphor-
ylated RS domain that are required for pre-mRNA splicing
and for subcellular localization. We also demonstrate the pres-
ence of a dominant nuclear retention signal (NRS) in the RS
domain of a nonshuttling SR protein, SC35, thereby providing
an explanation for why some SR proteins fail to shuttle.
MATERIALS AND METHODS
Expression plasmids. The SF2/ASF bacterial expression vector, pET9c-SF2
(R/S), and the mammalian expression vector, pCGT7-SF2/ASF, were previously
described (6, 31). In pCGT7-SF2/ASF, transcription is driven by the cytomega-
lovirus enhancer-promoter, and the coding sequence begins with an N-terminal
epitope tag, MASMTGGQQMG; this sequence corresponds to the first 11 res-
idues of the bacteriophage T7 gene 10 capsid protein and is recognized by the
T7.tag monoclonal antibody (Novagen). The SF2/ASF RS domain mutants RT,
RG, GS, KS, RS, and RS10 were previously described (4, 68) and were sub-
cloned into the epitope-tagged expression plasmid vector (6). The RE and RD
mutants were constructed by partial gene replacement essentially as described
for the other variants (4, 68) and were subcloned into the bacterial or mamma-
lian expression plasmid. Sequence analysis showed that there is a spurious as-
partate residue instead of the ninth glutamate in the RE mutant. Recombinant
SF2/ASF, RD, and RS10 were also subcloned into a bacterial expression plasmid
in which NdeI at the translation initiation site was converted to NcoI; although
the sequences of the proteins were not affected, higher expression levels were
obtained.
To generate the fusion constructs for nuclear retention studies, hnRNP A1
and SF2/ASF were independently amplified with specific primers that introduce
an SpeI site at the N terminus and an XbaI site followed by two stop codons and
a BamHI site at the C terminus. The resulting PCR products were purified,
digested with SpeI and BamHI, and subcloned into the corresponding sites of the
pCGT7 vector to generate pCGT7-A1-NRS and pCGT7-SF2-NRS. Subse-
quently, XbaI-BamHI fragments of pCGT7-SC35, pCGT7-NPc-RSSC35, or NPc-
RSSF2 (6) were subcloned into the corresponding sites of the pCGT7-A1-NRS or
pCGT7-SF2/ASF-NRS vector to generate pCGT7-A1/SC35, pCGT7-A1/rsSC35,
pCGT7-A1/rsSF2, pCGT7-SF2/SC35, and pCGT7-SF2/rsSC35. C-terminal dele-
tions in the RS domain of SC35 were introduced by PCR amplification of an
SC35 cDNA with specific primers, and the resulting products were subcloned
into the corresponding sites of the pCGT7 expression vector. Putative NRSs
identified within the SC35 RS domain were amplified with specific primers and
subcloned into the BamHI site of pCGT7-SF2/ASF, resulting in the fusion of the
SC35 putative NRSs downstream of the SF2/ASF coding sequence. The correct
orientation of the insert was verified by restriction mapping and DNA sequenc-
ing.
Oligonucleotides. The sequences of the specific primers used for PCR are
available upon request.
Expression and purification of recombinant proteins. Untagged wild-type and
variant recombinant SF2/ASF proteins were expressed and purified essentially as
described previously (68), except that the binding and elution properties were
different for the proteins. The peak fractions after chromatography under dena-
turing conditions were renatured by dialysis as described previously (68).
Cell cultures and transfections. HeLa cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum. Transfection was done
with 1 g of plasmid DNA per 60-mm dish of 60 to 75% confluent cells in the
presence of 20 g of Lipofectin (Gibco-BRL) (8). It was previously estimated
that the transiently expressed proteins accumulated in the transfected cells at
approximately fivefold higher levels than endogenous SF2/ASF (6, 8).
Indirect immunofluorescence. Cells were fixed and permeabilized for immu-
nofluorescence assays at 24 h after transfection. Fixation was done with 4%
p-formaldehyde in phosphate-buffered saline for 15 to 30 min at room temper-
ature, followed by incubation for 10 min in 0.2% Triton X-100. The fixed cells
were incubated for 1 h at room temperature with an anti-T7 monoclonal anti-
body (1:1,000; Novagen), washed with phosphate-buffered saline, and incubated
for 1 h at room temperature with fluorescein-conjugated goat anti-mouse im-
munoglobulin G (IgG) (1:200; Cappel Laboratories). The samples were observed
with a Zeiss Axioskop microscope, and the images were acquired with a Photo-
metrics CH250 cooled, charge-coupled device camera by using Digital Scientific
Smartcapture extensions in software from IP Lab Spectrum. The immunofluo-
rescence data reported are representative, and each experiment was reproduced
in multiple independent transfections.
Heterokaryon assays. For transient transfections involving interspecies het-
erokaryons, due to the need for a higher transfection efficiency, transfection was
carried out by electroporation with 10 g of plasmid DNA per 60-mm dish of 70
to 80% confluent cells in the presence of 20 g of carrier DNA. Transfected
HeLa cells were seeded on coverslips, followed by coincubation with an excess of
untransfected mouse NIH 3T3 cells for 3 h in the presence of 50 g of cyclo-
heximide/ml. The concentration of cycloheximide was then increased to 100
g/ml, and the cells were incubated for an additional 30 min prior to fusion. Cell
fusions were done as described previously (49), and the heterokaryons were
further incubated for 2 h in medium containing 100 g of cycloheximide/ml prior
to fixation. Immunofluorescence assays with the anti-T7 monoclonal antibody
were performed as described above, except that 4,6-diamidino-2-phenylindole
(DAPI) was included at 5 g/ml.
In vivo phosphorylation assays. HeLa cells were harvested 48 h after trans-
fection with Fugene-6. Cells (106) were scraped into 150 l of NP-40 lysis buffer
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40, 100 g of phenylmethyl-
sulfonyl fluoride [PMSF]/ml, 1 g of aprotinin/ml). The lysates were incubated
with or without 500 U of alkaline phosphatase (New England Biolabs, Beverly,
Mass.)/ml for 30 min at 37°C. Wild-type and mutant SF2/ASF proteins were
detected by Western blotting with the anti-T7 antibody (1:10,000 dilution).
Transcripts. 7CH3-GpppG-capped, 32P-labeled -globin and IgM M1-M2 pre-
mRNA substrates were made by runoff transcription from plasmids pSP64-H6
and pM1-M2 linearized with BamHI and XbaI, respectively (39).
In vitro splicing assays. HeLa cell nuclear and S100 extracts were prepared as
described previously (40). Standard conditions were used for the splicing reac-
tions (39). Briefly, 10 fmol of capped transcripts was incubated in 10-l splicing
reaction mixtures. Each reaction mixture contained either 30% nuclear extract or
35% S100 extract complemented with 4 or 8 pmol of wild-type or mutant
recombinant SF2/ASF. After incubation at 30°C for 4 h, the RNA was extracted
and analyzed on 5.5% polyacrylamide denaturing gels, followed by autoradiog-
raphy.
RESULTS
To dissect the compositional and primary sequence features
of an RS domain that are important for the functional, cellular
localization, and shuttling properties of an SR protein, we
constructed variants of human SF2/ASF with artificial domains
replacing the natural C-terminal RS domain (Fig. 1A). We
analyzed a series of mutant proteins in which either Arg or Ser
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residues within RS or SR dipeptide repeats of the RS domain
of SF2/ASF (residues 198 to 248) were substituted to generate
RT, RG, GS, and KS domains. Another mutant protein had all
of these Arg and Ser residues deleted while retaining other
potentially important amino acids present within this domain.
These mutant proteins, designated RT, RG, GS, KS, and RS,
have been described elsewhere (4). We also analyzed a mutant
version of SF2/ASF in which the entire RS domain was re-
placed by just 10 RS dipeptides (RS10) (68) and two new
mutants in which the RS dipeptides present in the RS domain
were replaced by RD or RE dipeptides (Fig. 1A). This com-
bination of mutant RS domains allowed us to systematically
analyze the specific requirements for Arg and Ser residues and
the importance of the interspersed residues, of potential sites
of phosphorylation by Ser/Thr protein kinases, and of alternat-
ing arginine and acidic residues.
RE and RD domains function in the in vitro splicing of RS
domain-dependent splicing substrates. We first examined
whether the new RE and RD domains, which mimic a hyper-
phosphorylated RS domain, can function as splicing activation
domains in vitro (Fig. 1B). To this end, we expressed these
proteins in bacteria, purified them, and compared their splicing
activities to those of recombinant wild-type SF2/ASF, RS,
and RS10. The IgM pre-mRNA substrate was previously
shown to require the RS domain for splicing, whereas the
-globin pre-mRNA does not (68). We confirmed that the RS
domain is required for IgM but not -globin pre-mRNA splic-
ing (Fig. 1B, lanes 1 to 6) and that the minimal RS domain—
which is rapidly phosphorylated by kinases in the extract
(68)—is also functional (Fig. 1B, IgM panel, lanes 7 and 8). We
also found that splicing could take place—albeit to reduced
extents—when the mutant RD and RE domains replaced the
natural domain (Fig. 1B, IgM panel, lanes 9 to 12). Thus, acidic
residues (either phosphorylated serines in RS10, aspartates in
RD, or glutamates in RE) alternating with basic residues (ar-
ginines) can mimic the structural and functional properties of
a natural phosphorylated RS domain that are required for
splicing in vitro. We do not know if the reduced splicing effi-
FIG. 1. In vitro splicing activities of SF2/ASF proteins with variant RS domains. (A) Sequences of SF2/ASF wild-type (wt) and variant RS
domains. All the Arg-Ser or Ser-Arg dipeptides in the RS domain of SF2/ASF were deleted (broken lines) to generate the RS mutant protein.
An additional mutant form in which the entire RS domain was deleted (RRM1/RRM2) behaved in a manner similar to that of the RS mutant
form. In addition, either Arg or Ser residues within RS or SR dipeptides were substituted with Thr, Gly, Lys, Asp, or Glu to generate RT, RG,
GS, KS, RD, or RE mutant proteins. The simplified RS10 domain consists of 10 consecutive RS dipeptides. RS or SR dipeptides as well as the
corresponding mutant dipeptides are indicated in bold. The RS, RRM1/RRM2, RT, RG, GS, KS, and RS10 mutant proteins were previously
described (4, 68). (B) In vitro splicing activities of the RS10, RE, and RD mutant proteins. Shown is the in vitro splicing of -globin pre-mRNA
(left panel) and IgM M1-M2 pre-mRNA (right panel) in HeLa cell nuclear extract (NE) (lanes 1), S100 extract alone (lanes 2), and S100 extract
complemented with 4 and 8 pmol of recombinant SF2/ASF (wild type [WT]) (lanes 3 and 4, respectively), RS (lanes 5 and 6, respectively), RS10
(lanes 7 and 8, respectively), RD (lanes 9 and 10, respectively), or RE (lanes 11 and 12, respectively).
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ciencies of the variant domains reflect suboptimal mimicry of
the natural RS domain or suboptimal folding after renatur-
ation of the proteins expressed in Escherichia coli. However,
the latter explanation is consistent with the observation that
the proteins with the artificial RD and RE domains also
showed reduced splicing efficiency for an RS domain-indepen-
dent pre-mRNA (Fig. 1B, -globin panel, lanes 9 to 12).
Structural requirements for the RS domain of SF2/ASF in
subcellular localization and targeting to nuclear speckles. We
next used the set of SF2/ASF variants to analyze the roles of
compositional features and specific residues within the RS
domain that are important for nuclear localization and target-
ing to the nuclear speckle compartment. We transiently over-
expressed epitope-tagged versions of the wild-type or mutant
cDNAs in HeLa cells and determined the subcellular distribu-
tion and subnuclear localization of the tagged proteins by in-
direct immunofluorescence microscopy. All constructs en-
coded proteins with a bacteriophage T7 gene 10 epitope tag at
the N terminus, allowing detection of the exogenous proteins
with a monoclonal antibody that recognizes this epitope. The
expression of the transfected cDNAs was analyzed by Western
blotting of whole-cell lysates and showed that all transiently
expressed proteins accumulated to similar levels and appeared
to be full length (Fig. 2A and data not shown).
The phosphorylation status of the transiently expressed
epitope-tagged proteins was analyzed by comparing the elec-
FIG. 2. Role of the RS domain of SF2/ASF in subcellular localization and distribution in nuclear speckles. (A) Immunoblot analysis of the
phosphorylation state of SF2/ASF wild-type (WT) and variant proteins. The indicated T7-tagged constructs were transfected into HeLa cells, total
cell lysates were incubated in the presence () or absence () of alkaline phosphatase (AP), and tagged SF2/ASF was detected by Western
blotting. Wild-type SF2/ASF and the RS10 mutant protein were phosphorylated in vivo, as indicated by the increase in mobility observed upon
treatment with alkaline phosphatase. In contrast, the RS, RD, and RE mutant proteins were not detectably phosphorylated in vivo. (B) HeLa
cells were transfected with plasmids encoding the indicated T7-tagged proteins and fixed at 24 h posttransfection. The localization of the expressed
proteins was determined by indirect immunofluorescence analysis with anti-T7 monoclonal antibody and fluorescein isothiocyanate-conjugated
secondary antibody. Bar, 5 m.
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trophoretic migration profiles of the respective proteins after
incubation in the presence or in the absence of alkaline phos-
phatase. An increase in the migration of wild-type SF2/ASF as
well as of the RS10 mutant protein after treatment with alka-
line phosphatase indicated that these proteins were phosphor-
ylated in HeLa cells (Fig. 2A). In contrast, the RS, RE, and
RD mutant proteins were not detectably phosphorylated in
vivo. It was previously shown that the GS mutant protein be-
comes phosphorylated but that the RG mutant protein does
not; we confirmed these results and also found that the RT and
KS mutant proteins did not display any change in mobility,
suggesting that they were not phosphorylated in vivo (45) (data
not shown).
Indirect immunofluorescence analysis with the anti-T7 anti-
body showed that at 24 h posttransfection, as expected, the
transiently expressed wild-type SF2/ASF protein was localized
exclusively in the nucleus, with a typical speckled pattern; in
contrast, the RS protein was localized in the nucleus but also
in the cytoplasm (Fig. 2B). In contrast, SF2/ASF variants con-
taining RT, RG, or KS domains, which were not phosphory-
lated in vivo, were localized aberrantly in the cell. The GS
mutant protein was present in nuclear speckles, although its
localization was not exclusively nuclear. Thus, a correlation
between phosphorylation of the C-terminal domain and proper
subcellular localization can be inferred, since the RS10 and GS
mutant proteins, which were phosphorylated in vivo, also were
localized to the nuclear speckle compartment (Fig. 2). The
RS10 domain and, to a lesser extent, the RD and RE domains
mediated proper subnuclear localization of the variant SF2/
ASF proteins in transfected cells, suggesting that a tract of 10
phosphorylated RS dipeptides is necessary and sufficient to
direct proper subcellular and intranuclear localization. In ap-
proximately 50% of transfected cells, SF2/ASF variants con-
taining RE and RE domains were localized in the nucleus but
also in the cytoplasm (Fig. 2B and data not shown). These
results show that alternating arginine and acidic residues ap-
parently mimic, at least to some extent, the structural and/or
functional properties of a natural RS domain that are required
for proper subcellular localization.
The minimal RS10 domain is sufficient to confer nucleocy-
toplasmic shuttling in the context of SF2/ASF. It was previ-
ously demonstrated that a bipartite signal consisting of RNA
binding mediated by RRMs and a specific RS domain deter-
mines the nucleocytoplasmic shuttling properties of a subset of
SR proteins (7). We used transient transfection in conjunction
with interspecies heterokaryons to assay for nucleocytoplasmic
shuttling of the RS10 mutant protein (Fig. 3). HeLa cells were
transfected with epitope-tagged cDNAs coding for wild-type
SF2/ASF or the RS10 variant and then were fused to mouse
NIH 3T3 cells to form heterokaryons. Prior to fusion, the cells
were treated with cycloheximide, so that no further protein
synthesis could take place in the heterokaryons. At 2 h post-
fusion, the cells were fixed and stained to examine the distri-
bution of the tagged proteins by immunofluorescence micros-
copy with a monoclonal antibody directed against the epitope
tag. To distinguish the human and mouse nuclei, the cells were
stained with DAPI, which gives a characteristic staining of
intranuclear bodies in mouse nuclei (49). The RS10 version of
SF2/ASF shuttled between the nucleus and the cytoplasm in
the same manner as the wild-type protein (Fig. 3), demonstrat-
FIG. 3. Analysis of nucleocytoplasmic shuttling of SF2/ASF and RS10 by transient expression in interspecies heterokaryons. Wild-type (WT)
SF2/ASF and the RS10 mutant protein were transiently expressed in HeLa cells. At 24 h posttransfection, the cells were treated with cycloheximide
and subsequently fused with mouse NIH 3T3 cells in the presence of polyethylene glycol to form heterokaryons. The cells were further incubated
for 2 h in the presence of cycloheximide, followed by fixation. (Left panels) The localization of the epitope-tagged proteins in the heterokaryons
was determined by indirect immunofluorescence analysis with anti-T7 monoclonal antibody (mAbT7) and fluorescein isothiocyanate-conjugated
secondary antibody. (Middle panels) The cells were simultaneously incubated with DAPI for differential staining of human and mouse nuclei within
heterokaryons. (Right panels) Phase-contrast images of the same heterokaryons. Arrows indicate the mouse nuclei within human-mouse
heterokaryons.
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ing that 10 RS dipeptides are necessary and sufficient to confer
nucleocytoplasmic shuttling in the context of the RNA-binding
domain of SF2/ASF. For the RS, RD, and RE proteins, the
incomplete nuclear localization at steady state precluded a
similar analysis of their shuttling properties.
NRSs in the RS domain of a nonshuttling SR protein. Very
little was known about the signals that distinguish shuttling
from nonshuttling SR proteins, and it was not clear whether
nonshuttling SR proteins are retained in the nucleus be-
cause they lack a nuclear export signal (NES) or because of
the presence of a nuclear retention signal (NRS). Although
the RS domain is part of the bipartite signal required for
nucleocytoplasmic shuttling and 10 consecutive RS dipep-
tides are necessary and sufficient for this process, SC35 has
two long stretches of RS repeats, yet it is not a shuttling
protein (Fig. 4A). This paradox suggested the existence of
an NRS in nonshuttling SR proteins, probably located
within their C-terminal RS domain (given previous results
obtained in RS domain swapping experiments [7]).
To investigate the presence of a putative NRS in SC35, we
FIG. 4. NRS in the RS domain of SC35. (A) Sequences of the SF2/ASF and SC35 RS domains. The long tracts of RS dipeptides are indicated
in grey, whereas RS dipeptides outside of these tracts are indicated in bold. (B) Analysis of nucleocytoplasmic shuttling of chimeric forms of
hnRNP A1 by transient expression in interspecies heterokaryons. Wild-type hnRNP A1 and chimeric proteins were transiently expressed in HeLa
cells, which were then fused with NIH 3T3 cells and analyzed as described in the legend to Fig. 3. Arrows indicate the mouse nuclei within
human-mouse heterokaryons. (C) Diagram showing the structures of chimeric proteins in which SC35, the RS domain of SC35, or the RS domain
of SF2/ASF was fused to a shuttling protein—either hnRNP A1 or SF2/ASF. The nuclear export properties of these chimeric proteins were
analyzed by interspecies heterokaryon assays (panel B) and by transcriptional inhibition assays (data not shown), and the results are summarized.
Act D, actinomycin D.
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constructed chimeric proteins in which SC35 or just its RS
domain was fused to a shuttling protein, either hnRNP A1 or
SF2/ASF (Fig. 4B and C). The nuclear export properties of
these chimeric proteins were analyzed by transcriptional inhi-
bition and interspecies heterokaryon assays (7, 43). The het-
erokaryon assay showed that chimeric proteins in which SC35
or its RS domain was fused to hnRNP A1 (hnRNP A1/SC35
and hnRNP A1/rsSC35) did not shuttle, as shown by the lack
of epitope tag staining in the nuclei of mouse cells (Fig. 4B and
C). In contrast, fusion of the RS domain of SF2/ASF to hnRNP
A1 (hnRNP A1/rsSF2) did not abolish nucleocytoplasmic shut-
tling of the resulting chimeric protein. The transcriptional in-
hibition assay is based on the observation that many shuttling
proteins accumulate in the cytoplasm when transcription is
inhibited (48). This independent assay also gave very similar
results: hnRNP A1, SF2/ASF, and the chimeric fusion hnRNP
A1/rsSF2 were localized to the cytoplasm in the presence of
actinomycin D, whereas fusion of SC35 or its RS domain to
hnRNP A1 or SF2/ASF prevented the cytoplasmic accumula-
tion of the resulting chimeras upon transcriptional inhibition
(Fig. 4C and data not shown). These experiments strongly
suggest the presence of an NRS sequence in the RS domain of
SC35.
We have determined that the nature of the RS domain
determines nucleocytoplasmic properties (7) and also that 10
consecutive RS dipeptides are necessary and sufficient to direct
nucleocytoplasmic shuttling in the context of SF2/ASF (Fig. 3).
The Drosophila homolog of human SF2/ASF (dSF2/ASF) lacks
a long tract of repeating RS dipeptides at the beginning of its
RS domain, which is essential for phosphorylation of the hu-
man protein by SR protein kinase 1 (SRPK1) (1). Whereas the
absence of these dipeptides has no effect on dSF2/ASF nuclear
localization, the protein does not show nucleocytoplasmic
shuttling. This finding strongly suggests that the RS dipeptides
in the RS domain and/or their phosphorylation are essential
for shuttling (1). A tract of eight RS dipeptides is present at the
N terminus of the human SF2/ASF RS domain (Fig. 4A), and
deletion of these residues results in nuclear retention (see
construct hSF2/ASF 197–216 in Fig. 4 of Allemand et al. [1]).
The RS domain of the nonshuttling protein SC35 has two such
tracts (eight and seven consecutive RS dipeptides separated by
33 residues, which also include eight additional RS dipeptides)
(Fig. 4A and 5A), yet it is retained in the nucleus. We specu-
lated that a putative NRS may be located within the C termi-
nus of SC35. To delineate more precisely this putative NRS in
SC35, we made two C-terminal deletions and tested whether
they relieved nuclear retention. The deletion mutant proteins,
termed SC35-RS1d and SC35-RS2d and lacking 45 and 30
amino acids, respectively, were able to shuttle between the
nucleus and the cytoplasm, as evidenced in heterokaryon as-
says (Fig. 5B). Thus, deletion of the last 30 amino acids in SC35
(SC35-RS2d) relieved nuclear retention and allowed nucleo-
cytoplasmic shuttling, confirming that this sequence comprises
a dominant NRS (Fig. 5C).
FIG. 4—Continued.
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Finally, we fused the NRS identified in SC35 to SF2/ASF
and found that the presence of these 30 amino acids conferred
nuclear retention to the otherwise shuttling protein SF2/ASF
(Fig. 6). Thus, the NRS identified in the RS domain of SC35 is
transferable, dominant, and sufficient to confer nuclear reten-
tion on NES-bearing proteins.
DISCUSSION
The RS domain is a distinctive feature of the SR family of
proteins and is also present in a family of related splicing
factors known as SR-like proteins. The strong phylogenetic
conservation of specific sequences within the RS domains led
to the suggestion of specific roles for the RS domains of indi-
vidual SR proteins. However, the RS domains are functionally
interchangeable in splicing and do not contribute to substrate
specificity (9, 41, 59). Moreover, chimeric proteins consisting
of the RRMs of SF2/ASF fused to RS domains from various
SR proteins can rescue cell viability in a chicken DT40 B-
lymphocyte cell line in which the endogenous SF2/ASF gene
has been inactivated (60). In contrast, analysis of the functional
specificity of RS domains in Drosophila demonstrated that not
all RS domains are functionally equivalent in their ability to
restore the function of the SR-like protein Tra2, which func-
tions in the sex determination alternative splicing cascade (12).
Our present results suggest that the high degree of sequence
conservation of individual RS domains may not be directly
related to their biochemical activities but rather may be related
to their ability to direct subcellular localization and influence
FIG. 5. C-terminal deletions in the RS domain of SC35 relieve
nuclear retention. (A) Sequences of the SC35 RS domain and of two
C-terminal deletions. The long tracts of RS dipeptides are indicated in
grey, whereas RS dipeptides outside of these tracts are indicated in
bold. (B) Analysis of nucleocytoplasmic shuttling of SC35 deletion
mutant proteins by transient expression in interspecies heterokaryons.
Wild-type SC35 and deletion proteins were transiently expressed in
HeLa cells, which were then fused with NIH 3T3 cells and analyzed as
described in the legend to Fig. 3. Arrows indicate the mouse nuclei
within human-mouse heterokaryons. (C) Sequence of the NRS present
in the RS domain of SC35.
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the ability of SR proteins to shuttle between the nucleus and
the cytoplasm.
Role of the RS domain in splicing. The RS domain of SF2/
ASF is not required for the in vitro splicing of all pre-mRNAs
(68). It is dispensable for the processing of several constitu-
tively spliced pre-mRNAs with strong splice sites; however, it is
required for the splicing of a mutant intron with a weakened
polypyrimidine tract and for some, but not all, exonic splicing
enhancer-dependent substrates. At least some of these RS
domain-dependent substrates also require U2AF35, the small
subunit of U2AF that specifically recognizes the AG dinucle-
otide at the 3 splice site (22, 42). These experiments suggested
that there are two pathways by which SR proteins promote
splicing, one of which is independent of the RS domain. Two
possible mechanisms for the latter activity of SR proteins can
be envisaged. First, other portions of the protein, besides the
RS domain, may mediate critical protein-protein interactions.
It has been shown that RRM2 of SF2/ASF has a dominant role
in both constitutive splicing and alternative splicing, suggesting
that this RRM module can mediate protein-protein interac-
tions (9, 11, 41, 59). Second, the binding of SF2/ASF to the
pre-mRNA via RRMs may be sufficient to promote splicing by
competing with inhibitory factors, such as hnRNPs, that antag-
onize SR proteins in splice site selection (15, 68).
Here, we show that the in vitro splicing of an RS domain-
dependent pre-mRNA can take place when a mutant RD, RE,
or RS10 domain replaces the natural domain. Thus, alternating
arginine and acidic residues appear to mimic the structural and
functional properties of a phosphorylated RS domain that are
required for splicing in vitro. Indeed, several splicing factors
possess natural RD and RE domains, sometimes in addition to
their RS domains (2, 56). Interestingly, some monoclonal an-
tibodies recognize structural features shared by several pro-
teins with domains rich in arginines alternating with gluta-
mates, aspartates, and/or phosphorylated serines (47).
Previous studies suggested that a dynamic phosphorylation
state, i.e., both serine hyperphosphorylation and hypophos-
phorylation of the natural RS domain, is required during dif-
ferent stages of splicing and can also affect the cellular local-
ization and recruitment of SR proteins (for a review, see
reference 44). The artificial RD and RE domains analyzed
here in the context of SF2/ASF do not undergo detectable
phosphorylation within the remaining serines, and the fact that
they can still promote splicing argues that the phosphorylation
and dephosphorylation of SF2/ASF are not strictly required for
splicing. We cannot rule out the possibility that some of the
residues that flank the artificial RD or RE repeats may un-
dergo cycles of phosphorylation and dephosphorylation, even
though we do not see any changes in electrophoretic mobility.
The suboptimal activities of the RD and RE mutant proteins
could indicate that a dynamic phosphorylation state is optimal
for splicing. In addition, RE and RD repeats may only imper-
fectly emulate some of the properties of hyperphosphorylated
FIG. 6. The NRS sequence identified in the RS domain of SC35 is transferable. (A) Diagram showing the structure of a chimeric protein in
which the NRS identified in the RS domain of SC35 was fused to SF2/ASF. (B) Analysis of nucleocytoplasmic shuttling by transient expression
in interspecies heterokaryons. Wild-type SF2/ASF and the chimeric protein SF2/NRS-SC35 were transiently expressed in HeLa cells, which were
then fused with NIH 3T3 cells and analyzed as described in the legend to Fig. 3. Arrows indicate the mouse nuclei within human-mouse
heterokaryons.
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RS repeats, and dephosphorylation of natural RS domains may
indeed be essential for splicing.
Nuclear localization of SR proteins. In this study, we show
that an RS domain consisting of 10 consecutive RS dipeptides
is sufficient to confer correct nuclear localization, targeting to
the nuclear speckles, and nucleocytoplasmic shuttling. We ob-
served a good correlation between the phosphorylation of the
RS domain and nuclear localization and also found that alter-
nating positive and negative charges (arginine and aspartic or
glutamic acid residues) at least partially mimic the functional
properties of a phosphorylated RS domain and direct proper
subcellular localization. RS domain-containing proteins do not
use the typical importin / import receptors but rather inter-
act with a nuclear import receptor that is specific for SR pro-
teins and for which two nearly identical genes, TRN-SR1 and
TRN-SR2, have been identified (28, 33). This SR protein-
specific import receptor shows sequence similarity to the im-
portin /transportin family. There is a single homologous gene
in the nematode Caenorhabitis elegans, termed CeTRN-SR,
which is essential for proper development (37).
The subcellular localization of SR proteins is influenced by
their phosphorylation state, which most likely affects both nu-
clear import and export. For instance, phosphorylation of the
RS domain is required for TRN-SR2-mediated nuclear import
of RS domain-containing proteins (33, 34). However, it is not
clear whether TRN-SR1 discriminates between phosphory-
lated and unphosphorylated SR proteins as import substrates.
Studies of a yeast SR protein-specific kinase homolog,
Sky1p, have suggested that a function of this type of kinase may
be to regulate nucleocytoplasmic shuttling of SR proteins. For
example, the nuclear import of human SC35 expressed in yeast
cells is severely inhibited when Sky1p is deleted, and a GFP-KS
mutant form of SF2/ASF that is not phosphorylated in vivo
localizes to the cytoplasm (64). Also, phosphorylation by Sky1p
of the shuttling protein Npl3p, a yeast hnRNP that contains
eight SR or RS dipeptides, promotes its dissociation from
exported messenger RNPs and also enhances its binding to the
Mtr10p import receptor in vivo (18).
The RS domain NLS may essentially consist of alternating
residues of opposite charges after serine phosphorylation; con-
sistent with this idea, we showed here that alternating positive
and negative charges—as in the RE and RD domains—are
also able to direct nuclear localization, suggesting that these
sequences can interact with the transportin-SR import system.
Therefore, the direct correlation between phosphorylation of
the RS domain and nuclear localization most likely reflects the
requirement for alternating charges to allow interactions with
the transportin-SR import system (33, 34). Thus, the RS do-
main NLS may behave as a regulated nuclear import signal,
and regulation of the accessibility of the NLS to the transport
machinery by phosphorylation is known to be a major mecha-
nism controlling the nucleocytoplasmic transport of proteins
(27). Phosphorylation of SR proteins also affects their nuclear
export. It has been shown that overexpression of the SR pro-
tein kinase Clk/Sty causes a diffuse distribution of SR proteins
in the nucleus, probably due to hyperphosphorylation of their
RS domains (10, 52), and also results in the cytoplasmic accu-
mulation of SF2/ASF (7). Overexpression of an SRPK2 kinase-
inactive mutant also results in the cytoplasmic accumulation of
SF2/ASF, apparently due to a stable interaction of SRPK2 with
SF2/ASF (30).
NESs and NRSs in the RS domains of SR proteins. The
number of proteins known to shuttle between the nucleus and
the cytoplasm is increasingly growing. Although the precise
function(s) of nucleocytoplasmic shuttling is not understood,
the emerging picture is that shuttling proteins convey informa-
tion on nuclear and cytoplasmic activities within the cell (17).
It is likely that shuttling proteins may have evolved to perform
different functions in the nucleus and in the cytoplasm, thus
constituting a group of multifunctional regulatory proteins that
control gene expression in both cellular compartments (for a
review, see references 54 and 61).
The recent findings that Drosophila SF2/ASF—which lacks a
continuous tract of RS dipeptides at the N terminus of its RS
domain—is a nonshuttling protein and that deletion of this RS
tract in human SF2/ASF results in its retention in the nucleus
indicated that such a tract of consecutive RS dipeptides is
necessary to promote shuttling in the context of human SF2/
ASF (1). Our present analysis of the human SF2/ASF RS10
variant confirms and extends these findings. The 20-amino-acid
minimal RS domain is both necessary and sufficient for the
protein to shuttle between the nucleus and the cytoplasm in the
context of the bipartite NES that also includes RNA binding.
We also demonstrated that SC35 is restricted to the nucleus
not because it lacks an NES but because it contains a dominant
NRS. There is little available information about nuclear reten-
tion of proteins. Specific sequences that mediate the retention
of proteins in the nucleus have been described, such as the one
that directs the localization of the shuttling protein nucleolin
to the nucleolus (53) or a region of approximately 200 amino
acids that mediates the nuclear retention of the La protein
(55). However, in none of these cases has it been shown
whether these proteins have transferable NRSs capable of con-
ferring nuclear retention on proteins that contain NESs.
An NRS has been identified in hnRNP C1, a nonshuttling
hnRNP (46), supporting the idea that nonshuttling hnRNPs
are confined to the nucleus due to signals that actively promote
their nuclear retention. The hnRNP C1 NRS was the first
sequence shown to retain NES-bearing proteins in the nucleus.
It comprises a core NRS sequence of 58 amino acids that
requires approximately 10 amino acids at both the amino and
the carboxyl termini for full NRS function. This proline-rich
NRS sequence contains clusters of basic residues, potential
phosphorylation sites for casein kinase II and protein kinase C,
and a potential glycosylation site (46).
Our present analysis of the shuttling properties of chimeric
proteins in which domains of SC35 were fused to either
hnRNP A1 or SF2/ASF determined that an NRS was present
within the RS domain of SC35. We made C-terminal deletions
in the RS domain of SC35 and determined that the NRS
mapped to a 30-amino-acid segment at the C terminus of the
RS domain, which comprises a proline-rich sequence (Fig. 5C).
Interestingly, the Drosophila homolog of human SC35, which
unlike its human counterpart has a short RS domain and shut-
tles between the nucleus and the cytoplasm, lacks this NRS
sequence (Jamal Tazi, personal communication). We have also
found that the human SC35 NRS sequence is portable and
dominant, since it confers nuclear retention to the shuttling
protein SF2/ASF (Fig. 6).
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Other than the proline-rich composition, there is no discern-
ible primary sequence similarity between the NRS sequences
identified in hnRNP C1 and SC35. Both sequences are proline
and serine rich and basic in character, at least in the absence of
phosphorylation. The only apparent similarity between the
NRS regions of SC35 and hnRNP C1 is at the level of their
secondary structures: they are both predicted to form exposed
loops (data not shown). The basic and serine-rich composition
of the SC35 NRS may be mostly a reflection of the similar
composition of the RS domain as a whole. Interestingly,
SRp40, which is also retained in the nucleus and has multiple
consecutive RS repeats (7), does not comprise a sequence with
obvious similarity to the SC35 NRS. Most likely, nuclear re-
tention is mediated by interactions of the NRS with nuclear
components which are yet to be defined. With regard to the
nuclear retention of RNA, it was recently shown that hy-
peredited, inosine-containing RNAs associate with a complex
of three proteins that appear to be structural components of
the nuclear matrix (p54nrb, PSF, and matrin 3) and mediate
their nuclear retention (67).
The shuttling ability of a subset of SR proteins resembles
that of hnRNP A1 and certain other hnRNPs (13, 49). Thus,
different SR proteins have unique intracellular transport prop-
erties, suggesting that family members that shuttle may have
roles in nuclear pre-mRNA splicing but also in mRNA trans-
port and/or in some cytoplasmic events. It has been proposed
that shuttling proteins, such as hnRNP A1, are involved in
mRNA export (25), and the role of two shuttling SR proteins,
SF2/ASF and 9G8, in the export of intronless mRNAs was
recently described (24). SF2/ASF has also been shown to mod-
ulate mRNA stability (35); however, this effect is highly selec-
tive for a PKCI-related mRNA, and it remains to be seen
whether SR proteins have a general role in controlling mRNA
stability. Conversely, nonshuttling hnRNPs containing NRSs
that override NESs may act to prevent the export of mRNA
transcripts that have not been fully processed from the nucleus
to the cytoplasm, where their translation would be detrimental
to the cell. The removal of nucleus-restricted SR and hnRNPs,
such as SC35, SRp40, and hnRNP C1, from messenger RNP
particles is likely to be critical to allow mRNA to be exported
from the nucleus. In contrast, the dissociation of shuttling SR
proteins from mature mRNA in vivo occurs in the cytoplasm,
where these and other proteins are presumably exchanged for
messenger RNPs, some of which are exclusively cytoplasmic.
In summary, we have extensively dissected the compositions
and sequences within an RS domain that are important for
promoting splicing, nuclear localization, and nucleoctyoplas-
mic shuttling. We have also shown that the retention of non-
shuttling SR proteins in the nucleus is due to the presence of
a dominant NRS rather than to the absence of an NES.
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